From Barchart: 2024-12-17 11:46:00

Zimmer Biomet (NYSE:ZBH) stock rose over 2% today after JPMorgan upgraded it to Overweight with a price target of $128, citing potential valuation improvement post-challenging 2024. Trading at 11.5–12.0x 2026 earnings, concerns lingered around execution and 2025 earnings. Analysts highlighted growth potential from product portfolio, steady procedure volumes, and reduced pricing pressure.

Despite execution risks, analysts see Zimmer Biomet well-positioned for multiple expansion towards 14.0–15.0x range. Improved product portfolio, steady procedure volumes, and conservative 2025 growth estimates of 4% organic revenue with potential for 5% by year-end support a more constructive outlook. Strong adoption of new product introductions in 2025 could drive multi-year growth story.



Read more at Barchart:: Zimmer Biomet Upgraded at JPMorgan, Shares Gain 2%